Luke Lee

Luke Lee



Luke joined Asset Management Ventures (AMV) in 2013, and is actively focused on data-driven healthcare investments, where he has experience in over 25 investments and exits.


While at Asset Management Ventures, he founded 3T Biosciences, a biotechnology company focused on developing novel immunotherapies and serves as the CEO. Additionally, Luke sourced AMV’s investment in Freenome, where he serves as a board observer.

Prior to Asset Management Ventures, Luke led a project team investigating the genomics landscape for Warburg Pincus that contributed to the formation of Helix, a consumer genomics company. He is also responsible for the formation and instruction of the course, “Valuation of Public Companies in the Life Sciences,” at Stanford. He has also consulted for Stanford Healthcare and serves as a mentor to A-Level Capital, a student-run venture fund.



Luke received his Ph.D. in Cancer Biology from Stanford University School of Medicine and received his Bachelor’s in Molecular and Cellular Biology from Johns Hopkins University.


AMV is a venture capital firm investing in
early-stage digital health, technology and
life sciences companies.

2595 E Bayshore Rd, Suite 240
Palo Alto, CA

© 2019 Asset Management Ventures
All Rights Reserved